Prognostic factors in patients with primary operable breast cancer (cT1-2N0-1M0) after reconstructive plastic surgery with single-stage reconstruction using endoprosthesis

Objective. To identify poor prognostic factors and event-free survival rates in patients with primary operable breast cancer (BC) after single-stage reconstruction. Subjects and methods. The investigation analyzed the data of 203 patients with BC who had undergone skin-sparing/subcutane-ous mastectomy (SSME/SCME) with single-stage reconstruction using a silicone endoprosthesis within combined or combination treatment between 2008 to March 2018. The patients’ mean age at the time of surgery was 45.08±0.65 years (range 18—75 years). The median follow-up was 51 months (95% CI: 49 to 53 months); the mean follow-up was 60.3±1.9 months. SCME with single-stage reconstruction with a silicone endoprosthesis was performed in 71.4% of patients. Results. The cumulative relapse-free survival at 3 and 5 years was 100%; that at 10 years was 92.6% (95% CI: 81.9—100%). The mean time to progression was 30.9 months. The distant metastasis-free survival at 3 years was 97% (95% CI: 94.7—99.4%); and that at 10 years was 91.6% (95% CI: 86.7—96.6%). The 10-year tumor-specific survival in the entire patient group was 99.3%. The presence of lymphovascular invasion (p=0.048) and regional lymph node metastasis (p=0.008) was associated with worse event-free survival. Conclusion. SSME/SCME with single-stage reconstruction using a silicone endoprosthesis is a safe surgical option for patients with BC. The risk of local recurrence and progression remains high within the next 5 years after the treatment and stable within the next 10 years. © 2022, Media Sphera Publishing Group. All rights reserved.